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Background: The inhaled corticosteroid ﬂuticasone furoate (FF) is efﬁcacious as a once-daily treatment
for the management of asthma. Asthma is associated with circadian changes, with worsening lung
function at night. We compared the efﬁcacy of once-daily FF in the morning or evening for the treatment
of asthma.
Methods: Adults with persistent bronchial asthma were enrolled into this randomised, repeat-dose,
double-blind, double-dummy, placebo-controlled, three-way crossover study. After a 14-day run-in
period, patients received either: FF 100 mg in the morning (AM); FF 100 mg in the evening (PM); or
placebo, via the ELLIPTA® dry powder inhaler. Patients received all three treatments (14 ± 2 day duration)
separated by a 14- to 21-day washout period. The primary endpoint was 24-h weighted mean forced
expiratory volume in 1 s (FEV1) measured at the end of each 14-day treatment.
Results: A total of 28 patients aged between 19 and 67 years were randomised and 21 (75%) completed
all three study arms. Once-daily administration of FF 100 mg resulted in an increased 24-hour weighted
mean FEV1; differences between the adjusted means for AM and PM FF dosing versus placebo were
0.077 L (90% conﬁdence interval [CI]: 0.001, 0.152) and 0.105 L (90% CI: 0.029, 0.180), respectively
(adjusted mean difference: e0.028 L [90% CI: e0.102, 0.045]). AM or PM doses had comparable in-
cidences of adverse events (AEs; 18/23 versus 18/24, respectively), no serious AEs occurred.
Conclusion: AM and PM doses of once-daily FF 100 mg produced comparable improvements in lung
function relative to placebo.
© 2016 The Authors. Published by Elsevier Ltd. This is an open access article under the CC BY-NC-ND
license (http://creativecommons.org/licenses/by-nc-nd/4.0/).1. Introduction
Asthma is a heterogeneous disease associated with airway
inﬂammation, which has been estimated to affect over 240 million
people worldwide [1]. Inhaled corticosteroids (ICS) are theCI, conﬁdence interval; FEV1,
e; FP, ﬂuticasone propionate;
agonist; PEF, peak expiratory
; SAE, serious adverse event;
infection.
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Ltd. This is an open access article umainstay of asthma treatment and are highly effective in reducing
both asthma symptoms and the risk of asthma-related exacerba-
tions, hospitalisations and death [2]. Although the importance of
anti-inﬂammatory treatment is generally considered to be under-
stood by patients with asthma, poor compliance with maintenance
ICS treatment remains an issue and is associated with poor asthma-
related outcomes [3]. For several ICS therapies, the frequency of
administration is an important determinant of their efﬁcacy and
safety. Older ICS that necessitated administration up to four times
daily have been largely superseded by twice-daily treatments, and
are now increasingly being replaced by once-daily regimens. In an
analysis of patient adherence to prescriptions in routine practice,
once-daily ICS dosing was shown to improve adherence by
approximately 20%, compared with twice-daily dosing [4]. How-
ever, it is important for a once-daily ICS to show similar efﬁcacy and
tolerability as the same dose given twice-daily.nder the CC BY-NC-ND license (http://creativecommons.org/licenses/by-nc-nd/4.0/).
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from ﬂuticasone propionate (FP) [5,6]. FF has greater glucocorticoid
receptor binding afﬁnity compared with other ICS [7], is highly
retained in human lung tissue and has a more prolonged duration
of anti-inﬂammatory activity than FP [8,9]. In clinical studies, once-
daily inhaled FF was shown to be efﬁcacious for pre-dose evening
forced expiratory volume in 1 s (FEV1) in patients with asthma
[10e12], and was non-inferior to the same dose given twice-daily
[13]. Inhaled FF monotherapy (100 mg and 200 mg; Arnuity
ELLIPTA®) is now approved in a number of countries for once-daily
treatment of asthma [14], as well as in combination with vilanterol
(a new long-acting beta2 agonist [LABA]), for the treatment of
chronic obstructive pulmonary disease and asthma [15,16].
Circadian changes have been demonstrated in asthma, with
lung function and symptoms worsening at night [17]. Sensitivity to
the time of administration has been observed for some once-daily
corticosteroids in asthma, where evening dosing has been asso-
ciated with optimal efﬁcacy and/or a reduction in cortisol-related
adverse effects [18,19]. Morning (AM) and evening (PM) dosing
schedules have been studied for a 400 mg dose of FF. Eight weeks
of treatment with FF 400 mg administered once-daily PM via the
DISKUS device or FF 200 mg administered twice-daily produced
similar improvements in pre-dose (trough) FEV1 [20]. In the same
study, FF 400 mg once-daily in the morning was effective but
resulted in a smaller improvement in pre-dose FEV1 compared
with FF 200 mg twice-daily or FF 400 mg once-daily PM adminis-
tration. The effects of altering the time of day of dosing with FF at
a clinically approved dose in asthma, delivered by the ELLIPTA dry
powder inhaler, have not been speciﬁcally studied. Flexibility
around the time of once-daily ICS administration to suit individual
patient preferences is considered to be beneﬁcial and may lead to
improved adherence with prescribed treatment. This study was
conducted to directly compare the efﬁcacy of once-daily FF 100 mg
administered either in the morning or evening in adult patients
with asthma.
2. Patients and methods
2.1. Study oversight
The study (GSK study number: FFA117156; clinicaltrials.gov
number: NCT01808339) was approved by the applicable institu-
tional review board and independent ethics committee, and was
conducted in accordancewith Good Clinical Practice guidelines and
the Declaration of Helsinki. All patients provided written informed
consent. Study FFA117156 was conducted between March 2013 and
March 2014 at the GSK Medicines Research Unit, New SouthWales,
Australia.
2.2. Study population
Men and women aged between 18 and 70 years were eligible
to be enrolled. All patients had persistent bronchial asthma, with a
pre-bronchodilator predicted FEV1 of 60% at screening [21]. All
patients were clinically stable on either low-to mid-dose ICS (for
example FP 100e250 mg twice-daily [total daily dose 200e500 mg]
or equivalent) with/without a short-acting beta2 agonist (SABA) or
a low-dose ICS/LABA combination (such as FP/salmeterol 100/
50 mg twice daily, FP/salmeterol 125/25 mg twice daily, or equiv-
alent) for at least four weeks preceding the screening visit. Pa-
tients demonstrated reversibility to salbutamol (albuterol) of
12% over baseline and an absolute change of 0.200 L within
60 min following four inhalations of albuterol/salbutamol aerosol
(400 mg total dose). The 60-min period was chosen to allow the
study site ﬂexibility to measure reversibility. SABAs or LABAs werewithheld for at least 6 or 24 h, respectively, prior to screening and
study visits. Eligible patients were current non-smokers (pack
history of 10 pack years), and had to be able to use the ELLIPTA
inhaler satisfactorily.
Patients were excluded if they had a history of life-threatening
asthma, any recent asthma exacerbation requiring oral corticoste-
roids (12 weeks prior to screening) or hospitalisation (6 months
prior to screening), a history of hypersensitivity or suspected
adverse reaction to components of the study medication, viral or
bacterial infection of the upper or lower respiratory tract requiring
antibiotics, or other diseases or contraindications that would put
the patient at risk.
2.3. Study design
This single-centre study was carried out according to a rando-
mised, repeat-dose, double-blind, double-dummy, placebo-
controlled, three-way crossover design. Eligible patients entered a
14-day run-in period, during which time they discontinued all their
usual asthma medications, with the exception of SABAs, which
were used as rescue medication throughout the study.
During the run-in period patients recorded morning (approxi-
mately 09.00 h) and evening (approximately 21.00 h) peak expi-
ratory ﬂow (PEF) on diary cards using an electronic PEF meter. Run-
in failures included patients who: resumed their normal asthma
medication (other than albuterol/salbutamol), experienced a severe
exacerbation (deterioration of asthma requiring the use of systemic
corticosteroids), or developed oral or respiratory infections that led
to a change in asthma management. To be eligible for random-
isation, daily diary compliance was required for all AM and PM data
on four or more of the last seven consecutive days of the run-in
period.
At the end of the run-in period, eligible patients were randomly
assigned to one of six sequences of three treatments delivered via
the ELLIPTA inhaler. All inhalers used in this study were identical,
and contained either FF or lactose (placebo). The 100 and 200 mg
doses of FF are both approved as monotherapy for the treatment of
persistent asthma in adults and adolescents in the USA. The FF
100 mg dose was selected for this study as it was considered likely
that this would be the most frequently prescribed clinical dose.
Treatment regimens were: A) FF AM with placebo PM; B) pla-
cebo AM with FF PM; C) placebo AM and PM. AM and PM doses
were administered at approximately 9:00 and 21:00 respectively.
The treatment period durations were 14 ± 2 days, separated by 14-
to 21-daywashout periods. The ﬁnal study day is referred to as ‘Day
14’, irrespective of the treatment period duration. Patients each
received their three series of treatments according to one of the
following sequences: ABC, ACB, BAC, BCA, CAB, CBA.
The ﬁrst dose of each treatment was administered on Day 1 PM,
and ﬁnal doses on Day 14 PM and Day 15 AM. FEV1 was measured
every 3 h for 0e24 h at the end of each treatment period (i.e. from
approximately 21:00 on Day 14 until 21:00 on Day 15). Patients
attended the clinic during this 24-h period and the FEV1 readings
were supervised by clinic staff.
Protocol-deﬁned stopping criteria for worsening asthma
included one or more of the following: 4 consecutive days in
which PEF (either AM, PM or both) fell below 80% of the mean AM
PEF recorded during the last 7 days of the run-in period; 3 days in
which 12 inhalations/day of albuterol/salbutamol were used; a
severe asthma exacerbation (a deterioration requiring the use of
systemic corticosteroids for 3 days, or an in-patient hospital-
isation or emergency department visit that required systemic cor-
ticosteroids); or clinical asthma worsening, which required
additional asthma treatment other than study medication or study
supplied albuterol/salbutamol.
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The primary endpoint, 24-hweightedmean FEV1 on Day 14, was
analysed to estimate the effect of AM or PM dosing. Secondary
endpoints included the effect of time of dosing on pre-treatment
FEV1 (measured on Day 14; AM and PM) and the safety (adverse
events [AEs]) of AM or PM dosing.
2.5. Statistical analysis
Whilst no formal hypothesis testing was performed, differences
between the three treatment regimens were compared using point
estimates and corresponding 90% conﬁdence intervals (CI), con-
structed for the difference between the adjusted mean of each test
treatment and the adjusted mean of the reference treatment.
Assuming a standard deviation (SD) of 0.16 L, an estimate based on
historical data [22]; a sample size of 20 patients was required to
have 90% power to detect a half-width difference of 0.085 L be-
tween AM, PM and placebo dosing for 24-h weighted-mean FEV1
during Day 14. This calculation was based on a symmetric two-
tailed procedure and a type I error rate of 10%.
Efﬁcacy analyses were performed by ﬁtting a mixed effects
analysis of covariance model onto the 0e24 h weighted mean FEV1.
Fixed-effect terms were applied for treatments (AM, PM, or pla-
cebo). The treatment period, patient baseline FEV1 (the mean
measurement over the three treatment periods), period baseline
FEV1 (the difference between each treatment period's baseline
measurement and the patient's baseline), gender and age were
ﬁtted as covariates; while the patient was ﬁtted as a random effect.
The difference between adjusted means and the corresponding
two-sided 90% CI for AMminus placebo, PMminus placebo and AM
minus PM were calculated.
2.6. Safety assessment
The incidence of all AEs (including treatment-related AEs, and
serious AEs [SAEs]) was collected throughout the study.
3. Results
3.1. Patients
An overview of the patient disposition is shown in Fig. 1.
Following the run-in period, 28 patients were randomised (safety/
‘all patients’ population), of which 25 (89%) were included in the
intent-to-treat population (deﬁned as patients who had at least one
baseline and one post-dose FEV1 measurement). A total of 21 pa-
tients (75%) completed all three study arms. Seven patients failed to
complete the study; ﬁve reached the protocol-deﬁned stopping
criteria (mainly asthma exacerbations), and two withdrew consent.
Demographic details and baseline lung function characteristics
for the ‘all patients’ population are presented in Table 1. Patients
were aged between 19 and 67 years at screening with a mean age of
31.7 years. Baseline mean pre-bronchodilator FEV1 was 86.9% of
predicted (range: 68.3e111.0%). All patients were required to
demonstrate 12% responsiveness to albuterol/salbutamol,
although one patient had a reversibility of 11.7%, which was
rounded up to 12%, and the patient was included in the study. There
were no signiﬁcant protocol deviations that could have affected the
study outcomes.
3.2. Primary endpoint: 0e24 h weighted mean FEV1 on day 14
FF 100 mg administered either AM or PM for 14 days was asso-
ciated with a similar increase in FEV1, compared with placebo, at alltime-points over the 0e24 h assessment period (Fig. 2). The
treatment difference in weighted mean FEV1, relative to placebo,
was comparable for FF 100 mg whether it was dosed AM (0.077 L) or
PM (0.105 L; Table 2). The difference between FF AM and FF PM
adjusted means was 0.028 L (Table 2).
3.3. Secondary endpoint: pre-treatment FEV1 (AM and PM) on day
14
There appeared to be no difference in pre-treatment FEV1 be-
tween the AM and PM FF dosing regimens (Table 3). Comparedwith
placebo, both FF 100 mg dosing regimens demonstrated higher pre-
treatment FEV1 values during Day 14, with differences in adjusted
means ranging from 0.013 to 0.114 L (AM and PM, respectively).
3.4. Secondary endpoint: safety
There were no SAEs observed during this study. A total of 133
AEs were experienced by 26 patients; all AEs had resolved by the
end of the study. AEs reported by  2 patients across all treatment
groups are shown in Table 4, the most common of which were
headache and upper respiratory tract infection (URTI). All AEs were
assessed asmild or moderate in intensity, with the exception of one
report of gastroenteritis that was severe, however this occurred
seven days after placebo administration and was considered un-
related to treatment.
Five patientsmet the pre-deﬁned lung function stopping criteria
(four consecutive days when PEF [AM, PM or both] was <80% of the
individual's baseline value) and were withdrawn from the study. At
withdrawal, four of the patients were receiving placebo and one
was receiving FF 100 mg PM dosing.
There were no obvious differences in the number of AE episodes
reported after AM or PM dosing. URTIs (viral and non-viral) were
reported by 15 patients (54%).
4. Discussion
This crossover study was conducted to investigate the effect of
the time of dosing, either in the morning or in the evening, on the
efﬁcacy of once-daily FF 100 mg in patients with persistent bron-
chial asthma. FEV1 was recorded at regular 3-h intervals 0e24 h
after dosing on Day 14. FEV1 was stable over this entire 24-h period,
with similar FEV1 proﬁles following AM or PM administration of FF
100 mg. Both morning and evening dosing with FF 100 mg produced
comparable increases in weighted mean FEV1 (0e24 h at the end of
the 14-day treatment period, the primary endpoint), with a mean
difference between AM and PM administration of 0.028 L (90%
CI: 0.102, 0.045). The difference from placebo was slightly lower
for morning administration (0.077 L; 90% CI: 0.001 L, 0.152 L),
compared with evening dosing (0.105 L; 90% CI: 0.029 L, 0.180 L).
Other studies have also demonstrated that morning and evening
doses of ICS are equally efﬁcacious. For example, FF/vilanterol had
comparable trough FEV1 on Day 14 after morning and evening
dosing [22] and mometasone furoate produced comparable
changes in symptom scores after morning and evening dosing [23].
Our study also included assessment of morning and evening
trough FEV1 as a secondary endpoint, as this parameter is
frequently used in larger clinical trials. On Day 14, morning and
evening trough FEV1 values were greater following AM or PM FF
100 mg, compared with placebo, with minor differences between
the AM and PM regimens supporting comparable efﬁcacy of FF
regardless of the timing of administration. The differences from
placebo were slightly less than those seen in large phase III trials.
For example, in a large, six-month, parallel group, phase III clinical
trial in patients with asthma, the mean difference from placebo in
Fig. 1. Patient disposition.
FEV1, forced expiratory volume in 1 s; BMI, body mass index; PEF, peak expiratory ﬂow; FF, ﬂuticasone furoate; AM, morning dose (approximately 09.00 h); PM, evening dose
(approximately 21.00 h).
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(95% CI: 0.036 L, 0.257 L) at 24 weeks [24]. In a 12-week phase III
study, the difference between FF 100 mg and placebo (evening
dosing) was 0.136 L (95% CI: 0.051 L, 0.222 L) [25]. The 0.114 L mean
difference from placebo in evening trough FEV1, with FF 100 mg
evening dosing observed in our studywaswithin the 95% CIs for the
same comparison in the 12-week phase III study. Patients in our
study had less severe asthma compared with the patients in the 12-
week phase III study (with 87% mean predicted pre-bronchodilator
FEV1 and mean baseline FEV1 of 3.087 L, compared with 70.49% [±
11.01% L SD] mean predicted pre-bronchodilator FEV1 and baseline
FEV1 of 2.290 L [± 0.617 L SD]) [25]. In our study, patients also
showed lower mean baseline FEV1 reversibility to salbutamol than
the 12-week phase III study patients (18%, compared with 30.66%
[± 19.74% SD], respectively) [25]. These differences in underlying
asthma severity are considered to be the most likely reason for the
lower trough FEV1 response to FF 100 mg seen in the present study.Although established ICS are typically administered twice-daily,
studies comparing their efﬁcacy (in terms of pre-dose FEV1) when
administered once-daily in the morning or evening in patients with
asthma have shown that evening dosing is as effective or is more
effective thanmorningdosing [18,26]. At a daily dose level above the
approved therapeutic range, FF 400 mg once-daily in the evening
produced similar efﬁcacy (pre-dose FEV1) to 200 mg twice-daily,
although a lesser effect was seen with FF 400 mg once-daily in the
morning [20]. By contrast, an early study with FF 100 mg adminis-
tered by a different dry powder inhaler (Rotadisk®Diskhaler) to that
used in the present study (ELLIPTA) showed similar efﬁcacy be-
tween morning and evening dosing [27]. The results of the present
studyare comparablewith the results obtained byMedleyet al. [27];
both studies were conducted at the same clinical dose.
In addition to circadian variations in lung function and airway
responsiveness, the circadian rhythm in serum cortisol has been
well characterised, with peak concentrations in the early morning
Table 1
Patient demographics and lung function at screening.
Characteristic Value
Mean age, years (range) 31.7 (19e67)
Gender, female/male, n (%) 15 (54)/13 (46)
Race, n (%)
White 21 (75)
Mixed Race 3 (11)
Asian 3 (11)
African Heritage 1 (4)
Mean pre-bronchodilator FEV1, L (SD) 3.087 (0.693)
Mean post-bronchodilator FEV1, L (SD) 3.641 (0.775)
Pre-bronchodilator FEV1% predicted, mean (range) 86.9 (68.3e111)
Post-bronchodilator FEV1% predicted, mean (range) 102 (87.5e127)
% reversibility, mean (range) 18.0 (11.7ae40.2)
FEV1, forced expiratory volume in 1 s; SD, standard deviation.
a One patient demonstrated reversibility of 11.7% and continued on the study.
Fig. 2. FEV1 over a 24-h period on Day 14, following administration of FF 100 mg AM or
PM and placebo for 14 days in patients with asthma (n ¼ 28). AM, morning dose
(approximately 09.00 h); CI, conﬁdence interval; FEV1, forced expiratory volume in 1 s;
FF, ﬂuticasone furoate; PM, evening dose (approximately 21.00 h).
Table 2
Statistical analysis of the weighted mean FEV1 (0e24 h) (L) on Day 14 following adminis
Comparison Adjusted means
Test Reference
FF 100 mg AM versus placebo 3.303 3.227
FF 100 mg PM versus placebo 3.332 3.227
FF 100 mg AM versus FF 100 mg PM 3.303 3.332
AM, morning dose (approximately 09.00 h); CI, conﬁdence interval; FEV1, forced expirato
Table 3
Statistical analysis of the pre-treatment FEV1 (L) on Day 14 following administration of F
Comparison Adjusted m
Test
AM pre-treatment FEV1 FF 100 mg AM versus placebo 3.299
FF 100 mg PM versus placebo 3.359
FF 100 mg AM versus FF 100 mg PM 3.299
PM pre-treatment FEV1 FF 100 mg AM versus placebo 3.236
FF 100 mg PM versus placebo 3.290
FF 100 mg AM versus FF 100 mg PM 3.236
AM, morning dose (approximately 09.00 h); CI, conﬁdence interval; FEV1, forced expirato
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cortisol has been reported with morning dosing compared with
evening dosing, indicating that evening dosing with ICS may be
optimal [19,28]. However, the pharmacokinetic-pharmacodynamic
relationship for the effects of FF on serum and urinary cortisol has
been extensively studied and clearly demonstrates that FF systemic
exposure at clinical doses is not associated with signiﬁcant cortisol
suppression [29]. In clinical studies in patients with persistent
asthma, FF doses <800 mg were not associated with urinary cortisol
suppression [11], with no effect on serum or urinary cortisol seen
after administration of clinical doses of FF 100 mg and 200 mg
(administered with vilanterol 25 mg) for 6 weeks [30]. Although an
effect of AM or PM dosing on cortisol has not been studied, based
on these data, an effect of FF 100 mg (dosed in either the morning
and evening) on serum or urinary cortisol was considered unlikely.
Dosing with FF 100 mg in themorning or evening for 14 days was
well tolerated in the patients with asthma participating in this
study. There were no obvious differences in the number of AEs
reported after morning or evening dosing and no SAEs were re-
ported during the study. In addition, all AEs following treatment
with FF were mild or moderate in intensity. Five patients were
withdrawn for meeting pre-deﬁned lung function stopping criteria;
four of these were receiving placebo at the time of withdrawal. The
incidence of URTIs (viral and non-viral) was comparable after AM
and PMdosing, similarly no difference in AE incidencewas seen in a
larger clinical trial comparing FF morning or evening dosing with
placebo [27].
A key strength of this study is that lung functionwas thoroughly
assessed at regular intervals over 24 h to determine the effects of FF
100 mg (AM or PM dosing). A limitation of the study is that the two-
week treatment period could be considered insufﬁcient to char-
acterise the long-term clinical efﬁcacy of an ICS. However, while a
further progressive improvement in lung function has been seen
with long-term ICS treatment, the majority of the beneﬁcial effects
of FF 100 mg were apparent after dosing for two weeks, with rela-
tively minor further improvements seen with treatment up to 26
weeks [31]. A further potential limitation of the study is that while
the sample size was sufﬁcient to provide an indication of the effect
of dosing time on the efﬁcacy of FF 100 mg in asthma, a much larger
study would be required to make conﬁrmatory claims regardingtration of FF 100 mg (AM or PM) and placebo for 14 days.
Difference in adjusted means 90% CI of the difference
0.077 (0.001, 0.152)
0.105 (0.029, 0.180)
0.028 (e0.102, 0.045)
ry volume in 1 s; FF, ﬂuticasone furoate; PM, evening dose (approximately 21.00 h).
F 100 mg (AM or PM) and placebo for 14 days.
eans Difference in adjusted means 90% CI of the difference
Reference
3.286 0.013 (e0.067, 0.093)
3.286 0.073 (e0.007, 0.153)
3.359 0.060 (e0.137, 0.018)
3.177 0.059 (e0.041, 0.160)
3.177 0.114 (0.013, 0.214)
3.290 0.054 (e0.152, 0.044)
ry volume in 1 s; FF, ﬂuticasone furoate; PM, evening dose (approximately 21.00 h).
Table 4
Adverse events reported by  2 patients across all treatment groups, following
administration of FF 100 mg (AM or PM) and placebo for 14 days.
N (%) Placebo
(n ¼ 25)
FF 100 mg AM
(n ¼ 23)
FF 100 mg PM
(n ¼ 24)
Total
(n ¼ 28)
Any event 16 (64) 18 (78) 18 (75) 26 (93)
Headache 9 (36) 12 (52) 10 (42) 18 (64)
URTI 2 (8) 6 (26) 1 (4) 7 (25)
Viral URTI 2 (8) 1 (4) 5 (21) 8 (29)
Nasopharyngitis 1 (4) 2 (9) 1 (4) 4 (14)
Gastroenteritis 3a (12) 1 (4) 0 3 (11)
Nausea 1 (4) 1 (4) 2 (8) 2 (7)
Vomiting 1 (4) 0 1 (4) 2 (7)
Eczema 2 (8) 1 (4) 0 3 (11)
Dysmenorrhoea 2 (8) 1 (4) 2 (8) 4 (14)
Seasonal allergy 0 1 (4) 1 (4) 2 (7)
AM, morning dose (approximately 09.00 h); FF, ﬂuticasone furoate; URTI, upper
respiratory tract infection; PM, evening dose (approximately 21.00 h).
a Including one case of viral gastroenteritis.
R.D. Kempsford et al. / Respiratory Medicine 112 (2016) 18e24 23equivalence of morning and evening dosing with FF. However, the
similar weighted mean FEV1 for morning and evening dosing with
FF 100 mg and comparable efﬁcacy to that seen in larger clinical
studies with FF 100 mg suggests that similar efﬁcacy would be
anticipated with morning or evening dosing with FF.
5. Conclusions
Once-daily administration of FF 100 mg for 14 days resulted in an
increased 0e24 h weighted mean FEV1, compared with placebo,
with no appreciable difference between morning or evening
dosing. Increases in trough FEV1 (AM or PM) were also comparable
between morning and evening dosing. There were no apparent
differences in the overall incidence of AEs following FF 100 mg
dosing in either the morning or evening.
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